Baidu
map

Clin Gastroenterol H:降低炎症性肠病患者再住院率的危险因素和干预措施

2019-09-04 xing.T MedSci原创

由此可见,对于接受IBD治疗的患者,30天和90天再入院率分别为18.1%和26.0%。IBD急性发作和感染是再入院的常见原因,疼痛控制不足和需要肠外营养是常见的危险因素。需要进行干预性研究以降低再入院风险。

近日,消化病领域权威杂志Clinical Gastroenterology and Hepatology发表了一篇研究文章,研究人员调查了接受治疗的炎症性肠病(IBD)患者30天和90天再入院率、原因、危险因素和干预措施,以减少这些患者的再入院率。

研究人员对2018年7月1日的之前发表的文献进行了系统检索,这些研究中的IBD患者接受药物治疗,并且报道了再入院率和相关原因及危险因素。研究人员的最终分析纳入了17项在接受过治疗的IBD住院成人中进行的队列研究(6324名患者),这些研究报告了再入院率和详细的病例评估。研究人员进行了随机效应荟萃分析,以估计30天和90天的再入院率,并确定与再入院相关的原因和危险因素。研究人员还对研究进行了定性分析,重点是减少再入院的干预措施。

总体而言,30天再入院率为18.1%(95%CI为14.4-22.4),90天再入院率为26.0%(95%CI为22.7-29.6)。在meta回归方面,溃疡性结肠炎患者比克罗恩病患者的研究报告了更高的再入院风险。再入院的最常见原因是IBD急性发作、感染或住院期间意外手术引起的并发症。30天再入院的危险因素是疼痛控制入院(比值比[OR]为2.27; 95%CI为1.69-3.03)、出院时需要全肠外营养(OR为2.13; 95%CI为1.36-3.35)以及入院时的计划或计划外手术(OR为3.11; 95%CI为2.27-4.25)。只有一项研究侧重于干预措施(专门的住院IBD服务),以降低再入院的风险。

由此可见,对于接受IBD治疗的患者,30天和90天再入院率分别为18.1%和26.0%。IBD急性发作和感染是再入院的常见原因,疼痛控制不足和需要肠外营养是常见的危险因素。需要进行干预性研究以降低再入院风险。 

原始出处:

Nghia H. Nguyen,et al.Rate of, Risk Factors for, and Interventions to Reduce Hospital Readmission in Patients with Inflammatory Bowel Diseases.Clinical gastroenterology and hepatology.2019.https://www.cghjournal.org/article/S1542-3565(19)30917-6/fulltext

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2072680, encodeId=b92c20e268003, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Wed Mar 18 13:46:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663238, encodeId=2e4f16632386a, content=<a href='/topic/show?id=91a330610e0' target=_blank style='color:#2F92EE;'>#再住院率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30610, encryptionId=91a330610e0, topicName=再住院率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=515025593328, createdName=12498974m59暂无昵称, createdTime=Fri May 15 10:46:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2064814, encodeId=1d64206481408, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Sun Jan 05 18:46:00 CST 2020, time=2020-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634549, encodeId=121e16345490a, content=<a href='/topic/show?id=b6974881243' target=_blank style='color:#2F92EE;'>#干预措施#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48812, encryptionId=b6974881243, topicName=干预措施)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a51a22195904, createdName=xiaoyang_ambs, createdTime=Wed Nov 20 02:46:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712073, encodeId=40f31e12073aa, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sun Sep 29 22:46:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547262, encodeId=1ea4154e2622a, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Fri Sep 06 06:46:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600026, encodeId=f0ff1600026b4, content=<a href='/topic/show?id=508e6e03203' target=_blank style='color:#2F92EE;'>#炎症性肠病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67032, encryptionId=508e6e03203, topicName=炎症性肠病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9fa18776644, createdName=huangshifeng, createdTime=Fri Sep 06 06:46:00 CST 2019, time=2019-09-06, status=1, ipAttribution=)]
    2020-03-18 许安
  2. [GetPortalCommentsPageByObjectIdResponse(id=2072680, encodeId=b92c20e268003, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Wed Mar 18 13:46:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663238, encodeId=2e4f16632386a, content=<a href='/topic/show?id=91a330610e0' target=_blank style='color:#2F92EE;'>#再住院率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30610, encryptionId=91a330610e0, topicName=再住院率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=515025593328, createdName=12498974m59暂无昵称, createdTime=Fri May 15 10:46:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2064814, encodeId=1d64206481408, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Sun Jan 05 18:46:00 CST 2020, time=2020-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634549, encodeId=121e16345490a, content=<a href='/topic/show?id=b6974881243' target=_blank style='color:#2F92EE;'>#干预措施#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48812, encryptionId=b6974881243, topicName=干预措施)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a51a22195904, createdName=xiaoyang_ambs, createdTime=Wed Nov 20 02:46:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712073, encodeId=40f31e12073aa, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sun Sep 29 22:46:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547262, encodeId=1ea4154e2622a, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Fri Sep 06 06:46:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600026, encodeId=f0ff1600026b4, content=<a href='/topic/show?id=508e6e03203' target=_blank style='color:#2F92EE;'>#炎症性肠病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67032, encryptionId=508e6e03203, topicName=炎症性肠病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9fa18776644, createdName=huangshifeng, createdTime=Fri Sep 06 06:46:00 CST 2019, time=2019-09-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2072680, encodeId=b92c20e268003, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Wed Mar 18 13:46:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663238, encodeId=2e4f16632386a, content=<a href='/topic/show?id=91a330610e0' target=_blank style='color:#2F92EE;'>#再住院率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30610, encryptionId=91a330610e0, topicName=再住院率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=515025593328, createdName=12498974m59暂无昵称, createdTime=Fri May 15 10:46:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2064814, encodeId=1d64206481408, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Sun Jan 05 18:46:00 CST 2020, time=2020-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634549, encodeId=121e16345490a, content=<a href='/topic/show?id=b6974881243' target=_blank style='color:#2F92EE;'>#干预措施#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48812, encryptionId=b6974881243, topicName=干预措施)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a51a22195904, createdName=xiaoyang_ambs, createdTime=Wed Nov 20 02:46:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712073, encodeId=40f31e12073aa, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sun Sep 29 22:46:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547262, encodeId=1ea4154e2622a, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Fri Sep 06 06:46:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600026, encodeId=f0ff1600026b4, content=<a href='/topic/show?id=508e6e03203' target=_blank style='color:#2F92EE;'>#炎症性肠病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67032, encryptionId=508e6e03203, topicName=炎症性肠病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9fa18776644, createdName=huangshifeng, createdTime=Fri Sep 06 06:46:00 CST 2019, time=2019-09-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2072680, encodeId=b92c20e268003, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Wed Mar 18 13:46:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663238, encodeId=2e4f16632386a, content=<a href='/topic/show?id=91a330610e0' target=_blank style='color:#2F92EE;'>#再住院率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30610, encryptionId=91a330610e0, topicName=再住院率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=515025593328, createdName=12498974m59暂无昵称, createdTime=Fri May 15 10:46:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2064814, encodeId=1d64206481408, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Sun Jan 05 18:46:00 CST 2020, time=2020-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634549, encodeId=121e16345490a, content=<a href='/topic/show?id=b6974881243' target=_blank style='color:#2F92EE;'>#干预措施#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48812, encryptionId=b6974881243, topicName=干预措施)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a51a22195904, createdName=xiaoyang_ambs, createdTime=Wed Nov 20 02:46:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712073, encodeId=40f31e12073aa, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sun Sep 29 22:46:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547262, encodeId=1ea4154e2622a, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Fri Sep 06 06:46:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600026, encodeId=f0ff1600026b4, content=<a href='/topic/show?id=508e6e03203' target=_blank style='color:#2F92EE;'>#炎症性肠病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67032, encryptionId=508e6e03203, topicName=炎症性肠病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9fa18776644, createdName=huangshifeng, createdTime=Fri Sep 06 06:46:00 CST 2019, time=2019-09-06, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2072680, encodeId=b92c20e268003, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Wed Mar 18 13:46:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663238, encodeId=2e4f16632386a, content=<a href='/topic/show?id=91a330610e0' target=_blank style='color:#2F92EE;'>#再住院率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30610, encryptionId=91a330610e0, topicName=再住院率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=515025593328, createdName=12498974m59暂无昵称, createdTime=Fri May 15 10:46:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2064814, encodeId=1d64206481408, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Sun Jan 05 18:46:00 CST 2020, time=2020-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634549, encodeId=121e16345490a, content=<a href='/topic/show?id=b6974881243' target=_blank style='color:#2F92EE;'>#干预措施#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48812, encryptionId=b6974881243, topicName=干预措施)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a51a22195904, createdName=xiaoyang_ambs, createdTime=Wed Nov 20 02:46:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712073, encodeId=40f31e12073aa, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sun Sep 29 22:46:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547262, encodeId=1ea4154e2622a, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Fri Sep 06 06:46:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600026, encodeId=f0ff1600026b4, content=<a href='/topic/show?id=508e6e03203' target=_blank style='color:#2F92EE;'>#炎症性肠病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67032, encryptionId=508e6e03203, topicName=炎症性肠病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9fa18776644, createdName=huangshifeng, createdTime=Fri Sep 06 06:46:00 CST 2019, time=2019-09-06, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2072680, encodeId=b92c20e268003, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Wed Mar 18 13:46:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663238, encodeId=2e4f16632386a, content=<a href='/topic/show?id=91a330610e0' target=_blank style='color:#2F92EE;'>#再住院率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30610, encryptionId=91a330610e0, topicName=再住院率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=515025593328, createdName=12498974m59暂无昵称, createdTime=Fri May 15 10:46:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2064814, encodeId=1d64206481408, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Sun Jan 05 18:46:00 CST 2020, time=2020-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634549, encodeId=121e16345490a, content=<a href='/topic/show?id=b6974881243' target=_blank style='color:#2F92EE;'>#干预措施#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48812, encryptionId=b6974881243, topicName=干预措施)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a51a22195904, createdName=xiaoyang_ambs, createdTime=Wed Nov 20 02:46:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712073, encodeId=40f31e12073aa, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sun Sep 29 22:46:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547262, encodeId=1ea4154e2622a, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Fri Sep 06 06:46:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600026, encodeId=f0ff1600026b4, content=<a href='/topic/show?id=508e6e03203' target=_blank style='color:#2F92EE;'>#炎症性肠病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67032, encryptionId=508e6e03203, topicName=炎症性肠病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9fa18776644, createdName=huangshifeng, createdTime=Fri Sep 06 06:46:00 CST 2019, time=2019-09-06, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2072680, encodeId=b92c20e268003, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Wed Mar 18 13:46:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663238, encodeId=2e4f16632386a, content=<a href='/topic/show?id=91a330610e0' target=_blank style='color:#2F92EE;'>#再住院率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30610, encryptionId=91a330610e0, topicName=再住院率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=515025593328, createdName=12498974m59暂无昵称, createdTime=Fri May 15 10:46:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2064814, encodeId=1d64206481408, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Sun Jan 05 18:46:00 CST 2020, time=2020-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634549, encodeId=121e16345490a, content=<a href='/topic/show?id=b6974881243' target=_blank style='color:#2F92EE;'>#干预措施#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48812, encryptionId=b6974881243, topicName=干预措施)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a51a22195904, createdName=xiaoyang_ambs, createdTime=Wed Nov 20 02:46:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712073, encodeId=40f31e12073aa, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sun Sep 29 22:46:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547262, encodeId=1ea4154e2622a, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Fri Sep 06 06:46:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600026, encodeId=f0ff1600026b4, content=<a href='/topic/show?id=508e6e03203' target=_blank style='color:#2F92EE;'>#炎症性肠病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67032, encryptionId=508e6e03203, topicName=炎症性肠病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9fa18776644, createdName=huangshifeng, createdTime=Fri Sep 06 06:46:00 CST 2019, time=2019-09-06, status=1, ipAttribution=)]

相关资讯

2019 亚洲工作组指南:饮食和炎症性肠病

亚洲工作组饮食和炎症性肠病指南主要介绍了亚洲国家IBD临床营养的多学科管理。指南主要基于现有的出版的文献证据,针对IBD的营养支持治疗以及初级营养治疗的相关数据提出了用于指导IBD患者营养支持治疗的38条实践建议。

GUT:anti-TNF并没有降低炎症性肠病患者的住院率和肠切除率

背景为了更好地了解生物疗法对克罗恩病(CD)和溃疡性结肠炎(UC)患者的现实影响,研究人员评估了英夫利昔单抗对患者住院率,手术率及支付药物成本产生的作用。方法研究人员使用了1995年至2012年间居住在加拿大安大略省的成人UC和CD患者的健康管理数据,进行分段回归分析的间歇时间序列设计来评估英夫利昔单抗对10年以上CD患者及5年以上UC患者住院率、手术率及公共药物支出的影响。结果与预期相比,英夫利

儿童炎症性肠病诊断和治疗专家共识

近年来,我国儿童炎症性肠病(IBD)发病率显著升高。国内及国际对儿童IBD诊治的研究进展很快,IBD的诊治水平有了很大提高。中华医学会儿科学分会消化学组和临床营养学组专家借鉴国外最新共识以及国内儿童IBD的临床研究和实践,在更新完善2010年儿童IBD诊断规范共识意见上增加治疗内容,形成新的诊治共识,为IBD患儿的临床管理提供指导意见。

Diabetes Care:二肽基肽酶4抑制剂与炎症性肠病风险

由此可见,基于人群的美国成人糖尿病队列研究表明,短期DPP4i治疗不会增加IBD风险。

GUT:肾素-血管紧张素系统(RAS)与炎症性肠病

研究认为RAS介导人类细胞的纤维化并在肠道炎症中受到干扰,靶向该系统的药物与改善疾病结局有关

JAMA Pediatr:患炎症性肠病的儿童患精神疾病的风险增加

根据瑞典Karolinska研究所发表于JAMA Pediatrics的一项新研究显示,患有炎症性肠病(IBD)的儿童患精神疾病的风险更大。

Baidu
map
Baidu
map
Baidu
map